Our top pick for
DiaMedica Therapeutics Inc is a biotechnology business based in the US. DiaMedica Therapeutics shares (DMAC) are listed on the NASDAQ and all prices are listed in US Dollars. DiaMedica Therapeutics employs 8 staff and has a market cap (total outstanding shares value) of USD$172.4 million.
|52-week range||USD$1.87 - USD$10.88|
|50-day moving average||USD$9.2659|
|200-day moving average||USD$6.361|
|Wall St. target price||USD$19.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.895|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-36.93%|
|Return on equity TTM||-53.59%|
|Market capitalisation||USD$172.4 million|
TTM: trailing 12 months
There are currently 82,969 DiaMedica Therapeutics shares held short by investors – that's known as DiaMedica Therapeutics's "short interest". This figure is 10.9% down from 93,069 last month.
There are a few different ways that this level of interest in shorting DiaMedica Therapeutics shares can be evaluated.
DiaMedica Therapeutics's "short interest ratio" (SIR) is the quantity of DiaMedica Therapeutics shares currently shorted divided by the average quantity of DiaMedica Therapeutics shares traded daily (recently around 169324.48979592). DiaMedica Therapeutics's SIR currently stands at 0.49. In other words for every 100,000 DiaMedica Therapeutics shares traded daily on the market, roughly 490 shares are currently held short.
However DiaMedica Therapeutics's short interest can also be evaluated against the total number of DiaMedica Therapeutics shares, or, against the total number of tradable DiaMedica Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DiaMedica Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 DiaMedica Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0047% of the tradable shares (for every 100,000 tradable DiaMedica Therapeutics shares, roughly 5 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against DiaMedica Therapeutics.
Find out more about how you can short DiaMedica Therapeutics stock.
We're not expecting DiaMedica Therapeutics to pay a dividend over the next 12 months.
DiaMedica Therapeutics's shares were split on a 1:20 basis on 15 November 2018. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your DiaMedica Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for DiaMedica Therapeutics shares which in turn could have impacted DiaMedica Therapeutics's share price.
Over the last 12 months, DiaMedica Therapeutics's shares have ranged in value from as little as $1.87 up to $10.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DiaMedica Therapeutics's is 2.4258. This would suggest that DiaMedica Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.